HISTORY

Fine Chemicals Division logo

Here at Johnson Matthey Fine Chemicals we have a rich history of innovation, dating back to our origins over 200 years ago. Scroll down to view key milestones throughout the course of our business and learn how we’ve grown to become a global, leading fine chemicals provider.

History

1815

The roots of Macfarlan Smith extend back to the early nineteenth century, when John Fletcher Macfarlan sets up his pharmacy in Edinburgh.

History

1817

Percival Norton Johnson establishes business as a gold assayer.

History

1820

Brothers Thomas and Henry Smith, both Licentiates of the Royal College of Surgeons, establish their own separate pharmacies in Edinburgh.

History

1847

Sir James Simpson discovers the anaesthetic properties of chloroform.

History

1851

George Matthey joins the company to form Johnson & Matthey.

History

1854

Macfarlan Smith morphine is used in the first ever hypodermic injection of a human.

History

1870

J.F. Macfarlan works with Joseph Lister, the pioneer of aseptic surgery, and produces the first sterile dressings.

History

1919

Johnson Matthey Inc. founded.

History

1958

Denatonium benzoate (Bitrex®) is identified. It is extremely bitter and is readily detected in the air and in any solution.

History

1970

Research with Michigan State University begins. This later leads to discovery of the platinum-based anti-cancer drug Cisplatin in 1977.

History

1973

Macfarlan Smith wins the Queen’s Award for Exports.

History

1975

Carboplatin is discovered.

History

1982

Bitrex® is officially recognised as the bitterest substance known to man by the Guinness World Records.

History

1983

Commercialisation of Johnson Matthey’s platinum-based anti-cancer drugs.

History

1983

West Deptford plant opens for manufacturing.

History

1985

Johnson Matthey expands its capabilities into Controlled Substances to gain synergy with existing security infrastructure for Precious Metals.

History

1991

Johnson Matthey receives the Queen’s Award for work on platinum-based anti-cancer drugs.

History

2000

The Devens, MA facility opens for business.

History

2001

Johnson Matthey PLC acquires Macfarlan Smith as an integral part of its Fine Chemicals Division.

History

2001

Development of large-scale chromatography and separations work at Devens, MA facility.

History

2002

Johnson Matthey acquires Pharm-Eco Laboratories.

History

2002

Johnson Matthey acquires Synetix.

History

2005

Devens facilities begin high potency operations.

History

2006

The dedicated pharma focused business unit is created - Catalysis and Chiral Technologies.

History

2010

Acquisition of X-Zyme means the addition of a biocatalysis platform.

History

2010

Commission of the Yantai China facility.

History

2010

Biocatalysis platform added.  X-Zyme acquisition.

History

2011

The grand opening of the Shanghai Catalyst plant.

History

2014

Acquisition of former GSK manufacturing site in Annan, Scotland.

History

2015

Realignment of the Fine Chemicals division under 4 core offerings: Custom Pharma Solutions, Controlled Substances, Catalysts and APIs & Life Cycle Management.

History

2015

Johnson Matthey acquire Pharmorphix® solid form business from Sigma-Aldrich bringing world-leading solid-state capabilities.